Neurotrope
Latest round
- Series A
Last raised
- Sep 2013
Total raised
- $21M
Investors
- 1
About Neurotrope
Neurotrope, Inc.Neurotrope, Inc. specializes in developing therapies for neurodegenerative conditions. Founded in 2011, the company is headquartered in New York, US. The CEO is Alan Tuchman.Neurotrope offers a range of proprietary products designed to address neurodegenerative diseases. Its primary product line includes advanced therapeutic solutions focused on Alzheimer's disease, enhancing patient care through innovative drug development.Neurotrope generates revenue primarily through a structured transactional model based on direct-to-consumer sales and partnerships with healthcare providers. Its pricing structure accommodates a variety of customer segments, ensuring that both individual patients and healthcare institutions can access its therapeutic solutions.Neurotrope plans to launch new therapeutic products targeting Alzheimer’s and other neurodegenerative diseases in the coming years, with specific timelines yet to be disclosed. The company is actively exploring expansion into European and Asian markets by 2025 to broaden its reach.
Who invested in Neurotrope
1 investor across 2 rounds
See all investors in Neurotrope
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Neurotrope
Who invested in Neurotrope?
Neurotrope has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Neurotrope raised?
Neurotrope has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Neurotrope last raise money?
Neurotrope's most recent round on record is a Series A, in Sep 2013.
What does Neurotrope do?
Neurotrope is a pharmaceuticals company.
Where is Neurotrope headquartered?
Neurotrope is headquartered in New York, US.
Which VCs invest in companies like Neurotrope?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Neurotrope's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Neurotrope? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.